Original Article
Disparities in Breast Cancer and African Ancestry: A Global Perspective
Lisa A. Newman MD, MPH, FACS, FASCO,
Corresponding Author
Lisa A. Newman MD, MPH, FACS, FASCO
Department of Surgery, Breast Care Center, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Address correspondence and reprint requests to: Lisa A. Newman, MD, MPH, FACS, FASCO, Professor of Surgery, Director, Breast Care Center, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA, or e-mail: [email protected]Search for more papers by this authorLisa A. Newman MD, MPH, FACS, FASCO,
Corresponding Author
Lisa A. Newman MD, MPH, FACS, FASCO
Department of Surgery, Breast Care Center, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Address correspondence and reprint requests to: Lisa A. Newman, MD, MPH, FACS, FASCO, Professor of Surgery, Director, Breast Care Center, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA, or e-mail: [email protected]Search for more papers by this authorAbstract
Recognition of breast cancer disparities between African-American and White American women has generated exciting research opportunities investigating the biologic and hereditary factors that contribute to the observed outcome differences, leading to international studies of breast cancer in Africa. The study of breast cancer in women with African ancestry has opened the door to unique investigations regarding breast cancer subtypes and the genetics of this disease. International research efforts can advance our understanding of race/ethnicity-associated breast cancer disparities within the USA; the pathogenesis of triple negative breast cancer; and hereditary susceptibility for breast cancer.
References
- 1Newman L, Fregene A. Breast cancer in African American women and women from sub-Saharan Africa. Cancer 2005; 103: 1540–50.
- 2 Surveillance, Epidemiology and End Results Program Fast Stats. Availbale at: http://seer.cancer.gov/faststats/selections (accessed September 25, 2014).
- 3Newman LA. Breast cancer disparities: high-risk breast cancer and African ancestry. Surg Oncol Clin N Am 2014; 23: 579–92.
- 4 Globocan. Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide. [Internet website]. 2001; Version 1.0. 2003. Available at: http://www-dep.iarc.fr/cgi-bin/exe/globosx1.exe?dtype=0select=0{00AMP00}value=11{00AMP00}sex=1 (accessed February 21, 2003).
- 5Stark A, Kleer CG, Martin I. African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer 2010; 116: 4926–32.
- 6Ries L, Eisner M, Kosary C. SEER Cancer Statistics Review, 1975-2002. 2005. Available at: http://seer.cancer.gov/csr/1975_2002/ (accessed March 9, 2006).
- 7Shamliyan T, Wang SY, Virnig BA, Tuttle TM, Kane RL. Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. J Natl Cancer Inst Monogr 2010; 2010: 121–9.
- 8Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer 2006; 106: 2104–12.
- 9Innos K, Horn-Ross PL. Risk of second primary breast cancers among women with ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2008; 111: 531–40.
- 10Collins LC, Achacoso N, Haque R. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat 2013; 139: 453–60.
- 11Bailes AA, Kuerer HM, Lari SA, Jones LA, Brewster AM. Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast. Cancer 2013; 119: 150–7.
- 12Roses RE, Arun BK, Lari SA. Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death. Ann Surg Oncol 2011; 18: 2873–8.
- 13Stark A, Stapp R, Raghunathan A. Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women. Breast Cancer Res Treat 2012; 131: 561–70.
- 14Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011; 125: 627–36.
- 15Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938–48.
- 16Alluri P, Newman LA. Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N Am 2014; 23: 567–77.
- 17Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2011; 16(Suppl 1): 61–70.
- 18Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: a population-based study. Cancer 2013; 119: 1611–7.
- 19Millikan RC, Newman B, Tse CK. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109: 123–39.
- 20Ma H, Wang Y, Sullivan-Halley J. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res 2010; 70: 575–87.
- 21Shinde SS, Forman MR, Kuerer HM. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer 2010; 116: 4933–43.
- 22Phipps AI, Buist DS, Malone KE. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control 2011; 22: 399–405.
- 23Yang XR, Chang-Claude J, Goode EL. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2011; 103: 250–63.
- 24Phipps AI, Chlebowski RT, Prentice R. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 2011; 103: 470–7.
- 25Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151: 727–37, W237-742.
- 26Amirikia KC, Mills P, Bush J, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young african-american women: implications for breast cancer screening recommendations. Cancer 2011; 117: 2747–53.
- 27Donenberg T, Lunn J, Curling D. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat 2011; 125: 591–6.
- 28Akbari MR, Donenberg T, Lunn J. The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas. Clin Genet 2014; 85: 64–7.
- 29Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 2001; 21: 1–18.
- 30Gilliland FD. Ethnic differences in cancer incidence: a marker for inherited susceptibility? Environ Health Perspect 1997; 105(Suppl 4): 897–900.
- 31Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. BioMed Research International 2013; 2013: 928562.
- 32Fejerman L, Haiman CA, Reich D. An admixture scan in 1,484 African American women with breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 3110–7.
- 33Ruiz-Narvaez EA, Rosenberg L, Yao S. Fine-mapping of the 6q25 locus identifies a novel SNP associated with breast cancer risk in African-American women. Carcinogenesis 2013; 34: 287–91.
- 34Rosenberg L, Boggs DA, Bethea TN, Wise LA, Adams-Campbell LL, Palmer JR. A prospective study of smoking and breast cancer risk among African-American women. Cancer Causes Control 2013; 24: 2207–15.
- 35Palmer JR, Ruiz-Narvaez EA, Rotimi CN. Genetic susceptibility loci for subtypes of breast cancer in an African American population. Cancer Epidemiol Biomarkers Prev 2013; 22: 127–34.
- 36Schwartz T, Stark A, Pang J. Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women. Cancer 2013; 119: 488–94.
- 37Pang J, Toy KA, Griffith KA. Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression. Breast Cancer Res Treat 2012; 135: 59–66.
- 38Lehmann BD, Bauer JA, Chen X. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750–67.
- 39Chen X, Li J, Gray WH. TNBCtype: a subtyping tool for triple-negative breast cancer. Cancer informatics 2012; 11: 147–56.
- 40Yu KD, Zhu R, Zhan M. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clin Cancer Res 2013; 19: 2723–33.
- 41Masuda H, Baggerly KA, Wang Y. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013; 19: 5533–40.
- 42McGhan LJ, McCullough AE, Protheroe CA. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol 2013; 21: 361–7.
- 43Thike AA, Yong-Zheng Chong L, Cheok PY. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer. Mod Pathol 2014; 27: 352–60.
- 44Shah PD, Gucalp A, Traina TA. The role of the androgen receptor in triple-negative breast cancer. Womens Health (Lond Engl) 2013; 9: 351–60.
- 45Mrklic I, Pogorelic Z, Capkun V, Tomic S. Expression of androgen receptors in triple negative breast carcinomas. Acta Histochem 2013; 115: 344–8.
- 46McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T, Sasano H. Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol 2013; 133: 66–76.
- 47Proctor E, Jiagge E, Kleer C. Androgen receptor expression in Ghanaian breast cancer cases: novel correlation with ALDH1 in triple-negative tumors. Paper presented at: Society of Surgical Oncology Annual Cancer Symposium 2014; Phoenix, AZ.
- 48 Surveillance, Epidemiology, and End Results program. Cancer Fast Stats. 2014. Available at: http://seer.cancer.gov/faststats/selections.php? (accessed February 26, 2014).
- 49Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90.
- 50Jaeger BA, Jueckstock J, Andergassen U. Evaluation of two different analytical methods for circulating tumor cell detection in peripheral blood of patients with primary breast cancer. BioMed research international 2014; 2014: 491459.
- 51Amirikia KC, Mills P, Bush J, Newman LA. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer 2011; 117: 2747–53.
- 52Fregene A, Newman LA. Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women? Cancer 2005; 103: 1540–50.
- 53Newman LA. Breast cancer in African-American women. Oncologist 2005; 10: 1–14.
- 54Trinkaus ME, Sayed S, Gakinya SM, Moloo Z, Hanna W, Rahim Y. Triple negative and basal-like breast cancer in East Africa. Breast J 2011; 17: 438–40.
- 55Roy I, Othieno E. Breast carcinoma in Uganda: microscopic study and receptor profile of 45 cases. Arch Pathol Lab Med 2011; 135: 194–9.
- 56Bird PA, Hill AG, Houssami N. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol 2008; 15: 1983–8.
- 57Dent R, Trudeau M, Pritchard KI. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13(15 Pt 1): 4429–34.
- 58Turkoz FP, Solak M, Petekkaya I. Association between common risk factors and molecular subtypes in breast cancer patients. Breast 2013; 22: 344–50.
- 59Fostira F, Tsitlaidou M, Papadimitriou C. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat 2012; 134: 353–62.
- 60Song Q, Huang R, Li J. The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10-year retrospective multi-center study in China. PLoS ONE 2013; 8: e72175.
- 61Carey LA, Perou CM, Livasy CA. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492–502.
- 62Morris GJ, Naidu S, Topham AK. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007; 110: 876–84.
- 63Lund MJ, Trivers KF, Porter PL. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009; 113: 357–70.
- 64Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG. Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer. Cancer 2008; 113: 2565–74.
- 65Sharma P, Klemp JR, Kimler BF. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. Breast Cancer Res Treat 2014; 145: 707–14.
- 66Greenup R, Buchanan A, Lorizio W. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol 2013; 20: 3254–8.
- 67Pal T, Bonner D, Kim J. Early onset breast cancer in a registry-based sample of African-american women: BRCA mutation prevalence, and other personal and system-level clinical characteristics. Breast J 2013; 19: 189–92.
- 68Nanda R, Schumm LP, Cummings S. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 2005; 294: 1925–33.
- 69Gao Q, Tomlinson G, Das S. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet 2000; 107: 186–91.
- 70Gao Q, Neuhausen S, Cummings S, Luce M, Olopade OI. Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer. Am J Hum Genet 1997; 60: 1233–6.
